Shares of Epizyme (NASDAQ:EPZM) have earned a consensus rating of “Buy” from the sixteen analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $23.64.
EPZM has been the topic of several recent research reports. Cann reissued a “buy” rating and issued a $26.00 price target on shares of Epizyme in a research note on Tuesday, December 12th. Oppenheimer set a $26.00 price target on Epizyme and gave the company a “buy” rating in a research note on Tuesday, December 12th. BidaskClub downgraded Epizyme from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 21st. Zacks Investment Research downgraded Epizyme from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Finally, Morgan Stanley initiated coverage on Epizyme in a research note on Wednesday, January 10th. They issued an “overweight” rating and a $20.00 price target on the stock.
Shares of EPZM traded down $1.50 during midday trading on Thursday, hitting $14.85. The stock had a trading volume of 514,308 shares, compared to its average volume of 442,865. Epizyme has a twelve month low of $9.30 and a twelve month high of $21.40. The company has a market capitalization of $1,031.18, a price-to-earnings ratio of -6.81 and a beta of 1.96.
In related news, COO Matthew Ros sold 72,264 shares of Epizyme stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $16.63, for a total value of $1,201,750.32. Following the sale, the chief operating officer now owns 74,867 shares of the company’s stock, valued at $1,245,038.21. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 25.20% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. increased its position in shares of Epizyme by 42.5% in the third quarter. Schwab Charles Investment Management Inc. now owns 217,168 shares of the biopharmaceutical company’s stock valued at $4,138,000 after acquiring an additional 64,721 shares during the last quarter. Macquarie Group Ltd. increased its position in shares of Epizyme by 105.5% in the third quarter. Macquarie Group Ltd. now owns 41,100 shares of the biopharmaceutical company’s stock valued at $783,000 after acquiring an additional 21,100 shares during the last quarter. University of Notre Dame DU Lac increased its position in shares of Epizyme by 6.7% in the fourth quarter. University of Notre Dame DU Lac now owns 204,600 shares of the biopharmaceutical company’s stock valued at $2,568,000 after acquiring an additional 12,881 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Epizyme in the fourth quarter valued at about $641,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Epizyme in the third quarter valued at about $17,591,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.